Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 double-blind randomized trial of intravenous efgartigimod in adult patients with primary Sjögren's syndrome
2021-005911-30Phase 2Completed
- Sponsor
- argenx
- Start
- Oct 2022
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in primary Sjögren's syndrome comparing Intravenous efgartigimod with Placebo (2 arms). Primary endpoint: Proportion of CRESS responders. Started Oct 2022; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
primary Sjögren's syndrome
Beyond the preview
Go deeper on 2021-005911-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005911-30.